Stereotaxis, Inc.

AMEX:STXS

Medical - Instruments & Supplies

Healthcare
$0.95 +2.53%

+$0.05 today

Market cap
$94.80M
Beta
1.32
P/E (TTM)
-8.3
EPS (TTM)
-$0.22
52W Low $1.70High $3.59

Volume 0.90M

Average 0.39M

STXS EBITDA Margin

EBITDA as a percentage of revenue.

Stereotaxis, Inc.AMEX: STXS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -86.9%

EBITDA Margin was -86.9% in Q1 FY2026, down 13.9 pp from a year earlier. On a trailing-twelve-month basis it was -64.4%, up 23.4 pp year over year. Over 3 fiscal years it widened by 1.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -60.7% for the fiscal year ending Dec 2026, up from -62.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-86.9%-27.5 pp QoQ
Last fiscal yearDec 2025
-62.0%+23.7 pp YoY
LTMMar 2026
-64.4%+23.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-13.9 pp-17.6 pp-3.7 pp
1 year+23.7 pp+1.4 pp-22.3 pp
3 years+1.4 pp——
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-62.0%
Year-over-year change
+23.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How STXS compares with its peers on the latest reported figures

  • STXS's LTM Mar 2026 EBITDA Margin of -64.4% is the 4th highest of the 5 companies compared; the peer median is -36.1%.
  • Its year-over-year change of +23.4 pp is the 2nd highest of 4, against a peer median of +3.1 pp.
  • Over three fiscal years its change of +1.4 pp compares with a peer median of +68.3 pp.
STXS Competitors Peer median
EBITDA Margin for STXS and competitors
Company Period LTM level YoY 3-year change
SSIISS Innovations International, Inc.LTM Mar 2026-7.7% +82.2 pp+350.1 pp
NPCENeuroPace, Inc.LTM Mar 2026-13.9% +3.1 pp+68.3 pp
CLPTClearPoint Neuro, Inc.LTM Mar 2026-58.2% +0.7 pp+19.4 pp
STXSStereotaxis, Inc.LTM Mar 2026-64.4% +23.4 pp+1.4 pp
MBOTMicrobot Medical Inc.LTM Mar 2026-13493.3% ——
Peer median (excluding STXS) -36.1%+3.1 pp+68.3 pp

Competitors are the stored peer set for STXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue35.02M28.15M26.77M26.92M32.38M
Cost of Revenue11.79M9.68M11.91M12.32M15.31M
Gross Profit23.23M18.47M14.86M14.59M17.07M
Gross Margin66.3%65.6%55.5%54.2%52.7%
Research & Development10.2M10.56M10.27M9.76M9.38M
Selling, General & Admin25.92M26.69M26.43M29.57M30.29M
Operating Expenses36.12M37.25M36.7M39.33M39.18M
Depreciation & Amortization106K429K595K969K1.56M
EBITDA(10.6M)(17.86M)(20.12M)(23.08M)(20.09M)
EBITDA Margin-30.3%-63.5%-75.1%-85.7%-62.0%
Operating Income(12.89M)(18.78M)(21.84M)(24.74M)(22.11M)
Operating Margin-36.8%-66.7%-81.6%-91.9%-68.3%
Interest Income0484K1.1M694K467K
Interest Expense10.07K0000
Other Income / Expenses2.17M484K1.13M694K469K
Income Before Tax(10.72M)(18.29M)(20.71M)(24.05M)(21.64M)
Pre-Tax Margin-30.6%-65.0%-77.4%-89.3%-66.8%
Income Tax Expense00000
Net Income(10.72M)(18.29M)(20.71M)(24.05M)(21.64M)
Net Margin-30.6%-65.0%-77.4%-89.3%-66.8%
EPS (Basic)(0.16)(0.26)(0.27)(0.30)(0.25)
EPS (Diluted)(0.16)(0.26)(0.27)(0.30)(0.25)
Weighted Avg Shares75.56M76.06M80.7M85.18M90.96M
Weighted Avg Shares (Diluted)75.56M76.06M80.7M85.18M90.96M

Stereotaxis, Inc.

AMEX:STXS

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.